CardiologyOnline.net

Cardiology Xagena

Search results for "Angiotensin receptor blocker"

The FDA ( Food and Drug Administration ) has approved its angiotensin receptor blocker ( sartan ) Candesartan Cilexetil ( Atacand ) for the treatment of heart failure ( NYHA II-IV and ejection fractio ...


The FDA ( Food and Drug Administration ) has approved a new use for angiotensin receptor blocker ( ARB ) Candesartan cilexetil ( Atacand ) tablets for the treatment of heart failure ( NYHA class II-IV ...


FDA ( Food and Drug Administration ) approved BiDil ( Isosorbide dinitrate/Hydralazine hydrochloride ) for the treatment of heart failure in black patients. BiDil is indicated to improve survival, ...


The EMA ( European Medicines Agency ) has finalised a review of Aliskiren-containing medicines, recommending that these medicines should be contraindicated in patients with diabetes or moderate to sev ...


The Honolulu-Asia Aging Study ( HAAS ) has examined the relationship of brain lesions and autopsy of treatment with a beta blocker, as compared with other drugs. The HAAS is a community-based study of ...


The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and imp ...


The FDA ( Food and Drug Administration ) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesart ...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system ( RAAS ) blockade with angiotensin-converting-enzyme inhibit ...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart ...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New ...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors ( ACEi ) and angiotensin receptor blockers ( ARBs; sarta ...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with Entresto ( Sacubitril / Valsartan ) tablets were readm ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan ) with or without beta block ...